// App-Quantinova.ai

P250 : Effect of secukinumab on radiographic progression through 2 years in patients with active PsA: end-of-study results from a Phase 3 study

Researchers

Presenter

  • Hasan Tahir

Principal Investigators

  • Philip Mease

  • Robert Landew

  • Proton Rahman

  • Atul Singhal

  • Elke Bttcher

  • Sandra Navarra

  • Aimee Readie

  • Shephard Mpofu

  • Eumorphia-Maria Delicha

  • Luminita Pricop

  • Dsire van der Heijde

Medical Centers

  • Department of Gastroenterology, Royal Free Hospital NHS Foundation Trust, London, UNITED KINGDOM

  • Department of Rheumatology, Swedish Medical Center and University of Washington, Seattle, WA

  • Department of Clinical Immunology and Rheumatology, University of Amsterdam and Atrium Medical Centre, Amsterdam, NETHERLANDS

  • Faculty of Medicine, Memorial University, St.John's

  • Southwest Rheumatology, Dallas, TX

  • Rheumazentrum Favoriten, Quellenstraße, Vienna, AUSTRIA

  • Department of Rheumatology, University of Santo Tomas Hospital, Manila, PHILIPPINES

  • Immunology, Dermatology and Rheumatology/Autoimmunity, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

  • Immunology, Hepatology, and Dermatology Development Unit, Novartis Pharma AG, Basel, SWITZERLAND

  • Department of Rheumatology, Leiden University Medical Centre, Leiden, UK

Locations

  • United Kingdom

  • United States

  • Netherlands

  • Canada

  • Austria

  • Philippines

  • Switzerland

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Tumor necrosis factor

Drug/Treatment

  • secukinumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Dose Escalation

Phase

  • III

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved